Biological monitoring: The role of toxicokinetics and physiologically based pharmacokinetic modeling

American Industrial Hygiene Association Journal

Volumn 60, Issue 2, 1999, Pages 237-242

  Mason, Howard ^a   Wilson, Kerr ^a  

^a HEALTH AND SAFETY LABORATORY   (United Kingdom)

Author keywords

Biological monitoring; Physiologically based pharmacokinetic (PBPK) modeling

Indexed keywords

CHEMICAL AGENT; VOLATILE AGENT;

ADIPOSE TISSUE; ARTICLE; BIOLOGICAL MONITORING; COMPARTMENT MODEL; GAS EXCHANGE; HEALTH HAZARD; LIVER; MUSCLE; OCCUPATIONAL EXPOSURE; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PROTECTIVE EQUIPMENT; SKIN; TOXICOKINETICS;

EID: 33847134212     PISSN: 00028894     EISSN: None     Source Type: Journal    
DOI: 10.1202/0002-8894(1999)060<0237:bmtrot>2.0.co;2     Document Type: Article

References (31)

1. Kehoe, R., F. Thamann, and J. Cholak: Lead absorption and excretion in certain trades. J. Ind. Hyg. 15:306-319 (1933).
2. Health & Safety Laboratory: Guidance on Laboratory Techniques in Occupational Medicine, vol 1. Sheffield, UK: Health & Safety Laboratory, 1996.
3. Lauwerys, R.R., and P. Hoet: Industrial Chemical Exposure: Guidelines for Biological Monitoring. Boca Raton, FL: Lewis Publishers, 1993.
4. American Conference on Governmental Industrial Hygienists (ACGIH): Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati OH: ACGIH, 1995.
5. Deutsche Forschungsgemeinschaft (DFG): Senatikommission zur Prufunggesundheitsschadlicher Arbeitsstoffe. Weinheim, Germany: VCH, 1995.
6. Health & Safety Executive: Occupational Exposure Limits 1997. Sudbury, Suffolk, UK: HSE Books, 1997.
7. Health & Safety Executive: Biological Monitoring in the Workplace. Sudbury, Suffolk, UK: HSE Books, 1997.
8. Teorell, T.: Kinetics of distribution of substances administered to the body. The extravascular mode of administration. Int. Arch. Pharmacodynamics 57:205-225 (1937).
9. Himmelstein, K., and R. Lutz: A review of the applications of physiologically based pharmacokinetic modeling. J. Phamacokinetics Biopharm. 7:127-145 (1979).
10. Gerlowski, L., and R. Jain: Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72:1103-1127 (1983).
11. Andersen, M., H. Clewell III, M. Gargas, F. Smith, and R. Reitz: Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87:185-205 (1987).
12. Leung, H-W: Use of physiologically based pharmacokinetic models to establish biological exposure indexes. Am. Ind. Hyg. Assoc. J. 53: 369-374 (1992).
13. Sultatos, L.: A physiologically based pharmacokinetic model of parathion based on chemical-specific parameters determined in-vitro. J. Am. Coll. Toxicol. 9:611-619 (1990).
14. Mann, S., P-O. Droz, and M. Vahter: A physiologically based pharmacokinetic model for arsenic exposure. II, Validation and application in humans. Toxicol. Appl. Pharmacol. 140:471-486 (1996).
15. O'Flaherty, E.: A pharmacokinetic model for chromium. Toxicol. Lett. 68:145-157 (1993).
16. International Commission on Radiological Effect: Report of the Task Group on Reference Man, vol. 23. Oxford: Pergamon Press, 1975.
17. Droz, P-O., and V. Fiserova-Bergerova: Biological monitoring VI. Pharmacokinetic models in setting biological exposure indices. Appl. Occup. Environ. Hyg. 7:574-580(1992).
18. Droz, P-O., M. Berode, and M. Wu: Evaluation of concomitant biological and air monitoring results. Appl. Ind. Hyg. 6:465-474 (1991).
19. Roach, S.: A more rational basis for air sampling programmes. Am. Ind. Hyg. Assoc. J. 27:1-12 (1966).
20. Fiserova-Bergerova, V., J. Vlach, and J. Cassady: Predictable "individual differences" in uptake and excretion of gases and lipid soluble vapours simulation study. Br. J. Ind. Med. 37:42-49 (1980).
21. Droz, P-O., M. Wu, W. Cumberland, and M. Berode: Variability in biological monitoring of solvent exposure: I Development of a population physiological model. Br. J. Ind. Med. 46:42-49 (1989).
22. Dankovic, D., and J. Bailer: The impact of exercise and intersubject variability on dose estimates for dichloromethanc derived from a physiologically based pharmacokinetic model. Fund. Appl. Toxicol. 22:20-25 (1994).
23. Silvaggio, T., and D. Mattison: Setting occupational health standards: toxicokinetic differences among and between men and women. J. Occup. Med. 36:849-854 (1994).
24. Shelley, M., M. Andersen, and J. Fisher: A risk assessment approach for nursing infants exposed to volatile organics through the mother's occupational inhalation exposure. Appl. Ind. Hyg. 4:21-26 (1989).
25. Thomas, R.S., P.L. BigelowL, T.J. Keefe, and R.S.H. Yang: Variability in biological exposure indices using physiologically based pharmacokinetic modeling and Monte Carlo simulation. Am. Ind. Hyg. Assoc. J. 57:23-32 (1996).
26. Wrighton, S., and J. Stevens: The human hepatic cytochromes p450 involved in drug metabolism. Crit. Rev. Toxicol. 22:1-21 (1992).
27. Reitz, R., A. Mendrala, and F. Guengerich: In-vitro metabolism of methylene chloride in human and animal tissues: use in PBPK models. Toxicol. Appl. Pharmacol. 97:230-246 (1989).
28. Hallier, E., K. Asmuth, A. Dommermuth, B. Aust, and H. Goergens: Metabolism of dichloromethane to formaldehyde in human erythrocytes: polymorphism of glutathione transferase theta (GST T1-1). Arch. Toxicol. 68:423-427 (1994).
29. Roy, A., C.P. Weisel, P.J. Lioy, and P.G. Georgopoulus: A distributed parameter physiologically-based pharmacokinetic model for dermal and inhalation exposure to volatile organic chemicals. Risk Anal. 16:147-160 (1996).
30. Health & Safety Executive: Occupational Exposure Limits 1996. Sudbury, Suffolk, UK: HSE Books, 1996.
31. Cocker, J., B. Nutley, and H. Wilson: Methylene-bis-orthochloroaniline (MbOCA): towards a biological monitoring guidance value. Biomarkers 1:185-189 (1996).